NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report released on Thursday,Benzinga reports. The brokerage currently has a $19.00 price target on the stock.

NRXP has been the topic of a number of other research reports. Ascendiant Capital Markets upped their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. D. Boral Capital restated a “buy” rating and issued a $31.00 target price on shares of NRx Pharmaceuticals in a research note on Monday.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP opened at $2.07 on Thursday. The firm has a 50-day moving average of $2.88 and a two-hundred day moving average of $2.03. The stock has a market cap of $35.02 million, a P/E ratio of -0.97 and a beta of 1.22. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). As a group, equities analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of NRXP. Townsquare Capital LLC acquired a new stake in NRx Pharmaceuticals during the third quarter worth about $25,000. Anson Funds Management LP acquired a new stake in NRx Pharmaceuticals during the third quarter worth about $241,000. Sassicaia Capital Advisers LLC acquired a new stake in NRx Pharmaceuticals during the fourth quarter worth about $33,000. AdvisorShares Investments LLC raised its stake in NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after acquiring an additional 180,229 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at approximately $61,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.